Literature DB >> 25054291

Biomarkers usher in era of personalized care for malignant glioma patients.

Arnab Chakravarti1, Kamalakannan Palanichamy, Erica Hlavin Bell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 25054291      PMCID： PMC6178276          DOI： 10.2217/cns.12.10

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  13 in total

Review 1.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

2.  Clinical significance of molecular biomarkers in glioblastoma.

Authors:  C Ang; M-C Guiot; A V Ramanakumar; D Roberge; P Kavan
Journal:  Can J Neurol Sci       Date:  2010-09       Impact factor: 2.104

3.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

Review 4.  Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

Authors:  Michael Jansen; Stephen Yip; David N Louis
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

5.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Authors:  Andreana L Rivera; Christopher E Pelloski; Mark R Gilbert; Howard Colman; Clarissa De La Cruz; Erik P Sulman; B Nebiyou Bekele; Kenneth D Aldape
Journal:  Neuro Oncol       Date:  2009-12-14       Impact factor: 12.300

Review 6.  O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.

Authors:  Prerana Jha; Vaishali Suri; Ayushi Jain; Mehar Chand Sharma; Pankaj Pathak; Pankaj Jha; Arti Srivastava; Ashish Suri; Deepak Gupta; Kunzang Chosdol; Parthoprasad Chattopadhyay; Chitra Sarkar
Journal:  Neurosurgery       Date:  2010-12       Impact factor: 4.654

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 9.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.

Authors:  Kenneth Aldape; Peter C Burger; Arie Perry
Journal:  Arch Pathol Lab Med       Date:  2007-02       Impact factor: 5.534

10.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.